Ethical frameworks in clinical research processes during COVID-19: a scoping review.


Journal

BMJ open
ISSN: 2044-6055
Titre abrégé: BMJ Open
Pays: England
ID NLM: 101552874

Informations de publication

Date de publication:
23 07 2021
Historique:
entrez: 24 7 2021
pubmed: 25 7 2021
medline: 30 7 2021
Statut: epublish

Résumé

In response to the COVID-19 pandemic there have been significant developments in research, its conduct and the supporting ethical framework. While many protocols have been delayed, halted or modified, other research efforts have been accelerated, generating controversy. The goal of this paper is to determine the rates of references surrounding the ethical oversight of research as reported in current COVID-19-related research publications. Scoping review. Population-based observational or interventional studies from December 2019 to May 2020 with sample size of two or more. Studies were searched through electronic databases including Medline, EMBASE, and Cochrane CENTRAL Register of Controlled Trials. Eligibility criteria included participants within published studies who tested positive for COVID-19. Data were extracted and charting methods included taking note of references to ethical frameworks, institutional review board (IRB), ethics committee (EC) or research ethics board (REB) involvement, consent processes, and other variables. 11 556 articles were screened, with 656 included in the final analysis. References to ethics were present in 530 (80.8%) studies, with 491 (74.8%) involving IRB/ECs/REBs and 126 (19.2%) not referencing ethics. Consent processes were outlined in 201 (30.6%) studies, with 198 (30.2%) reporting that they obtained consent waivers, however, 257 (39.2%) did not mention consent at all. Differences (p<0.001) in ethics-related references were apparent when analysed by continent, publication type, sample size and IF. The majority of published articles pertaining to COVID-19 research made mention of ethical considerations, however, national and regional variations in research ethics review requirements introduce heterogeneity between studies and raise important questions about the conduct of scientific research during global public emergencies. Open Science Framework: https://osfio/z67wb.

Identifiants

pubmed: 34301656
pii: bmjopen-2020-047076
doi: 10.1136/bmjopen-2020-047076
pmc: PMC8313312
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

e047076

Informations de copyright

© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: None declared.

Références

Lancet. 2020 Apr 11;395(10231):1225-1228
pubmed: 32178769
Eur J Cancer. 2007 Sep;43(14):2124-33
pubmed: 17714938
Cancer Res. 2005 Dec 15;65(24):11597-604
pubmed: 16357170
Med Res Rev. 2021 Mar;41(2):725-738
pubmed: 33174617
J Med Ethics. 2020 Jul;46(7):419-420
pubmed: 32601258
JAMA. 2013 Nov 27;310(20):2191-4
pubmed: 24141714
Ann Intern Med. 2018 Oct 2;169(7):467-473
pubmed: 30178033
Contemp Clin Trials Commun. 2016 Aug 15;3:74-79
pubmed: 27822565
J Am Coll Dent. 2014 Summer;81(3):4-13
pubmed: 25951677

Auteurs

Lawrence Kasherman (L)

Division of Medical Oncology and Hematology, Princess Margaret Hospital Cancer Centre, Toronto, Ontario, Canada.
Department of Medical Oncology, St George Hospital, Kogarah, New South Wales, Australia.
St George and Sutherland Clinical Schools, University of New South Wales, Kogarah, New South Wales, Australia.

Ainhoa Madariaga (A)

Division of Medical Oncology and Hematology, Princess Margaret Hospital Cancer Centre, Toronto, Ontario, Canada.
Autonomous University of Barcelona, Barcelona, Spain.

Qin Liu (Q)

Division of Medical Oncology and Hematology, Princess Margaret Hospital Cancer Centre, Toronto, Ontario, Canada.
Department of Haematology, St George Hospital, Kogarah, New South Wales, Australia.

Luisa Bonilla (L)

Division of Medical Oncology and Hematology, Princess Margaret Hospital Cancer Centre, Toronto, Ontario, Canada.

Michelle McMullen (M)

Division of Medical Oncology and Hematology, Princess Margaret Hospital Cancer Centre, Toronto, Ontario, Canada.
Department of Medical Oncology, Sir Charles Gairdner Hospital, Nedlands, Western Australia, Australia.

Shiru Lucy Liu (SL)

Division of Medical Oncology and Hematology, Princess Margaret Hospital Cancer Centre, Toronto, Ontario, Canada.
British Columbia Cancer Agency, Surrey, British Columbia, Canada.

Lisa Wang (L)

University of Toronto, Toronto, Ontario, Canada.

Rouhi Fazelzad (R)

Division of Medical Oncology and Hematology, Princess Margaret Hospital Cancer Centre, Toronto, Ontario, Canada.

Katherine Karakasis (K)

Division of Medical Oncology and Hematology, Princess Margaret Hospital Cancer Centre, Toronto, Ontario, Canada.

Ann M Heesters (AM)

University of Toronto, Toronto, Ontario, Canada.
University Health Network, Toronto, Ontario, Canada.

Amit M Oza (AM)

Division of Medical Oncology and Hematology, Princess Margaret Hospital Cancer Centre, Toronto, Ontario, Canada amit.oza@uhn.ca.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH